Get the Stockscreener App
3.785
1.69%
-0.065
Black Diamond Therapeutics Inc stock is traded at $3.785, with a volume of 517.86K.
It is down -1.69% in the last 24 hours and down -3.69% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$3.85
Open:
$3.885
24h Volume:
517.86K
Relative Volume:
0.53
Market Cap:
$215.37M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-2.0133
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
-4.66%
1M Performance:
-3.69%
6M Performance:
+88.31%
1Y Performance:
+50.80%
1-Day Range:
$3.67
$3.885
1-Week Range:
$3.665
$4.055
52-Week Range:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
3.78 | 219.35M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.94 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.23 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.13 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.22 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Resumed | Piper Sandler | Overweight |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Black Diamond Therapeutics Inc. (BDTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about Black Diamond Therapeutics Inc. stockQuarterly Profit Review & Fast Exit and Entry Strategy Plans - newser.com
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout (NASDAQ:BDTX) - Seeking Alpha
Will Black Diamond Therapeutics Inc. stock pay special dividends2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Piper Sandler - Defense World
Can Black Diamond Therapeutics Inc. stock hit record highs againJuly 2025 Review & Comprehensive Market Scan Reports - newser.com
Will Black Diamond Therapeutics Inc. stock maintain momentum in 2025July 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Volume spikes in Black Diamond Therapeutics Inc. stock – what they meanQuarterly Growth Report & Expert Curated Trade Setups - newser.com
How geopolitical tensions affect Black Diamond Therapeutics Inc. stockJuly 2025 Short Interest & AI Powered Market Entry Strategies - newser.com
It makes sense and dollars to buy Black Diamond Therapeutics Inc (BDTX) stock - Setenews
How to read the order book for Black Diamond Therapeutics Inc.Earnings Recap Summary & Expert Verified Stock Movement Alerts - newser.com
Piper Sandler Assumes Coverage on BDTX with Overweight Rating | - GuruFocus
Tools to assess Black Diamond Therapeutics Inc.’s risk profileMarket Rally & Weekly Market Pulse Updates - newser.com
Can Black Diamond Therapeutics Inc. stock outperform in 2025 bull marketQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
15,800 Shares in Black Diamond Therapeutics, Inc. $BDTX Bought by Bailard Inc. - Defense World
Is Black Diamond Therapeutics Inc. trending in predictive chart models2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Real time scanner hits for Black Diamond Therapeutics Inc. explained2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
What is HC Wainwright’s Estimate for BDTX FY2025 Earnings? - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO) - The Globe and Mail
Black Diamond Therapeutics files for mixed shelf of up to $500 millionSEC filing - MarketScreener
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):